Ariel Galapo Kann

机构：Hospital Alemão Oswaldo Cruz · ORCID：0000-0002-7260-2030

发表论文 31 篇 · 总被引 1289 次 · h-index 10

代表论文

• Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer (2024 · New England Journal of Medicine · 被引 380)
• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer (2023 · Journal of Clinical Oncology · 被引 336)
• Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial (2022 · The Lancet · 被引 242)
• ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (2025 · New England Journal of Medicine · 被引 123)
• The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer (2023 · JACC CardioOncology · 被引 56)
• Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09) (2024 · Journal of Clinical Oncology · 被引 26)